GeneNews™ is a molecular diagnostics company focused on developing and commercializing proprietary blood-based diagnostic tests for early disease detection, determining the stage of disease and monitoring its progression, treatment or recurrence. Tests based on the company's breakthrough Sentinel Principle® are being developed in the areas of cancer, cardiovascular diseases, psychiatric disorders, central nervous system diseases and arthritis. The company’s lead product in its Sentry line of blood tests is ColonSentry®, a test for determining an individual’s current risk for colorectal cancer.
Now available in Canada, USA, Malaysia and China. For more information, please visit www.colonsentry.com